Grufity logo
Grufity logo
GLTO

GLTO - Galecto Inc Stock Price, Fair Value and News

$28.10+1.26 (+4.69%)
Market Closed as of 11 Sep 2026, 04:00 pm ET

Price Targets

GLTO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

GLTO Price Action

Last 7 days

-6.5%

Last 30 days

-9.3%

Last 90 days

35.2%

Trailing 12 Months

903.6%

GLTO RSI Chart

GLTO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

GLTO Valuation

Market Cap

1.7B

Price/Earnings (Trailing)

-6.6

EV/EBITDA

-4.7

Price/Free Cashflow

-38.99

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

GLTO Fundamentals

GLTO Earnings

Earnings (TTM)

-262.8M

Earnings Growth (Yr)

-807.01%

Earnings Growth (Qtr)

-12.21%

GLTO Profitability

Return on Equity

-50.93%

Return on Assets

-48.35%

Free Cashflow Yield

-2.56%

GLTO Investor Care

Dividend Yield

0%

Dividend/Share (TTM)

0

Shares Dilution (1Y)

4560.83%

Diluted EPS (TTM)

7.49

Revenue & Growth

How Galecto Inc generates revenue and covers its expenses, based on the latest reported earnings.

About Galecto Inc

GLTO
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled small molecule inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.
 CEO
 WEBSITEhttps://galecto.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES45

Galecto Inc Frequently Asked Questions

GLTO is the stock ticker symbol of Galecto Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Sep 11 2026, market cap of Galecto Inc is 1.73 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.